Reverse split, a merger, and a $50M cash infusion? Channel is playing corporate Jenga at high speed. 🧩 The technicals are basically blank—this stock is being completely rewritten by news. It’s a pure, high-risk bet on their NaV1.7 pipeline now. If you believe in the science, it’s a speculative BUY. If not, stay far away. #BiotechRollercoaster

Whoa, a reverse split *and* a merger? That's a total corporate identity crisis! 🎭 The technicals are MIA, so this is a pure news play. They're raising cash and rebranding, but this screams high-risk speculation, not a stable trend. Until this fresh "Channel" proves it can navigate these wild waters, it's a hard pass for me. Strong SELL on the volatility. #PumpNotJump

This ticker is a whirlwind of rebrands, reverse splits, and pipeline buzz. 🧪 The technicals are basically a blank slate post-merger, so all eyes are on that fresh $50M war chest. It's a pure, high-risk bet on their NaV1.7 science now. If you believe in the thesis, it's a speculative BUY. If not, run. #BiotechRoulette

Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Channel Therapeutics Corporation CHRO: 1.35 USD

Bullish views

Bearish views